Abstract Number: 027 • 2020 Pediatric Rheumatology Symposium
Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition
Background/Purpose: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy And Elevated Temperature (CANDLE) Syndrome is an autoinflammatory interferonopathy caused by mutations in the genes encoding for components…Abstract Number: 59 • 2019 ACR/ARP Annual Meeting
Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Background/Purpose: Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway have demonstrated efficacy in immune-mediated diseases and haves been identified as therapeutic…Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…Abstract Number: 543 • 2019 ACR/ARP Annual Meeting
Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T…Abstract Number: 850 • 2019 ACR/ARP Annual Meeting
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Background/Purpose: To assess the most recent safety-data of synthetic (s) and biological (b)DMARDs to inform the 2019 update of the EULAR recommendations for the management…Abstract Number: 992 • 2019 ACR/ARP Annual Meeting
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
Background/Purpose: Janus kinases (JAKs) play critical roles in mediating various cytokine signaling. First-generation non-selective JAK inhibitors such as tofacitinib and baricitinib are widely used for…Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…Abstract Number: 1419 • 2019 ACR/ARP Annual Meeting
Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Background/Purpose: Network meta-analyses (NMA) have been conducted to compare the efficacy and safety of sarilumab, a fully human monoclonal antibody against the interleukin 6 receptor…Abstract Number: 1420 • 2019 ACR/ARP Annual Meeting
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Background/Purpose: In many countries, JAK-inhibitors (JAKi) have been recently accepted for the treatment of patients with rheumatoid arthritis (RA). However, prescription patterns may differ notably…Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…Abstract Number: 2030 • 2019 ACR/ARP Annual Meeting
Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
Background/Purpose: Background/Purpose: Cutaneous inflammation is recurrent in systemic lupus erythematosus (SLE) and is often triggered by exposure to ultraviolet B (UVB) light. Type I interferons…Abstract Number: 2358 • 2019 ACR/ARP Annual Meeting
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis…Abstract Number: L09 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
Background/Purpose: A potentially increased risk of venous thromboembolism (VTE) was noted in pre-marketing trials of baricitinib, which is a Janus kinase inhibitor (JAK-I). This led…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »